BioRestorative Therapies, Inc. (BRTX) P/E Ratio History
Deep ValueTrading at -0.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2023–2023
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, BioRestorative Therapies, Inc. (BRTX) trades at a price-to-earnings ratio of -0.1x, with a stock price of $1.52 and trailing twelve-month earnings per share of $-12.47.
The current P/E is 118% below its 5-year average of 0.7x. Over the past five years, BRTX's P/E has ranged from a low of 0.7x to a high of 0.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, BRTX trades at a 100% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, BRTX trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BRTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BRTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BRTX P/E vs Peers
Regenerative & Stem Cell Medicine peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 27.5 | 0.59Best | -44% | |
| $32B | 36.7 | 8.67 | +171%Best | |
| $258B | 36.4 | 17.23 | +7% | |
| $10B | 10.1Lowest | - | +143% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BRTX Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Dec 31 2023 | $1.74 | $2.64 | 0.7x | +0% |
Average P/E for displayed period: 0.7x
BRTX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BRTX — Frequently Asked Questions
Quick answers to the most common questions about buying BRTX stock.
What is BRTX's P/E ratio?
BioRestorative Therapies, Inc. (BRTX) trailing twelve-month P/E ratio is -0.1x, based on TTM diluted EPS of $-12.47. The 5-year average P/E is 0.7x and the historical range spans 0.7x to 0.7x.
Is BRTX stock overvalued or undervalued?
BRTX trades at -0.1x P/E, below its 5-year average of 0.7x. At the 0th percentile of its historical range (0.7x–0.7x), the stock is priced at a discount to its own history.
Is BRTX stock expensive?
No, BRTX is not expensive on a historical basis. The current P/E of -0.1x is below the 5-year average of 0.7x and sits at the 0th percentile of its valuation range.
What is BRTX's historical P/E range?
Over the past 5 years, BRTX's P/E ratio has ranged from 0.7x to 0.7x, with a median of 0.7x and an average of 0.7x. The current P/E of -0.1x places the stock at the 0th percentile of this range. Full historical data spans 2023–2023.
How does BRTX's P/E compare to the S&P 500?
BRTX trades at -0.1x P/E versus the S&P 500 median of 21.8x. The 100% discount to the market suggests lower growth expectations or perceived higher risk.
How does BRTX's valuation compare to Healthcare peers?
BioRestorative Therapies, Inc. P/E of -0.1x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BRTX's PEG ratio?
BRTX PEG ratio is N/A, based on a P/E of -0.1x and EPS growth of -36.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BRTX's earnings yield?
BRTX earnings yield is N/A, the inverse of its -0.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.